TERN Terns Pharmaceuticals Inc
1,433
$5.56
$0.30
(5.12%)
| Watchers | 1,433 |
| 52-Wk Low | $3.26 |
| 52-Wk High | $13.23 |
| Market Cap | $359.59M |
| Volume | 568,611.00 |
| 52-Wk High | $13.23 |
| 52-Wk Low | $3.26 |
Commit To Purchase Terns Pharmaceuticals At $5, Earn 37.2% Annualized Using OptionsStock Options Channel • about 1 month ago
Investors considering a purchase of Terns Pharmaceuticals Inc (TERN) stock, but tentative about paying the going market price of 6.72/share, might benefit from considering selling puts among the...
Share to Feed
Terns Pharmaceuticals (NASDAQ:TERN - Free Report) had its price target decreased by UBS Group from $19.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. UBS Group...
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Terns Pharmaceuticals (TERN Research Report) on March 27 and set a price t...
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price target reduced by equities research analysts at UBS Group from $19.00 to $18.00 in a report released on Wednesday, Benzinga...
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price objective lowered by investment analysts at JMP Securities from $17.00 to $15.00 in a research report issued on Monday...
Terns Pharmaceuticals (NASDAQ:TERN Get Free Report) had its price objective upped by stock analysts at BMO Capital Markets from $18.00 to $19.00 in a research report issued to clients and...
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN Research Report) and Spruce Biosciences...
In trading on Monday, shares of Terns Pharmaceuticals Inc (TERN) crossed below their 200 day moving average of 6.58, changing hands as low as 6.30 per share. Terns Pharmaceuticals Inc...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Interim data from initial dose escalation cohorts from Phase 1 trial of TERN-701 (allosteric BCR-ABL) for treatment of CML expected in second half of 2024 Top-line data from Phase 1 trial...